Santen SAS
🇫🇷France
NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye
Phase 2
Completed
- Conditions
- Dry Eye
- Interventions
- Drug: NOVA22007 ''Cyclosporine''Drug: vehicle/placebo
- First Posted Date
- 2008-08-21
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Santen SAS
- Target Recruit Count
- 132
- Registration Number
- NCT00739349
- Locations
- 🇺🇸
Central Maine Eye Care, PA, Lewiston, Maine, United States
Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
Phase 1
Completed
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: NOVA63035 "Corticosteroid"
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Santen SAS
- Target Recruit Count
- 20
- Registration Number
- NCT00665106
- Locations
- 🇺🇸
Midwest Eye Institute, Indianapolis, Indiana, United States
Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)
Phase 2
Completed
- Conditions
- Conjunctivitis, Vernal
- Interventions
- First Posted Date
- 2006-05-22
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Santen SAS
- Target Recruit Count
- 118
- Registration Number
- NCT00328653
- Locations
- 🇫🇷
Groupe Hospitalier Bichat-Claude Bernard, Paris, France
© Copyright 2025. All Rights Reserved by MedPath